CoChat

GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma

Open access
Park, Jeong A., Cheung, Nai-Kong V. · 2020 · Journal of Hematology & Oncology

The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.

Abstract

Background: The cure rate for metastatic osteosarcoma has not substantially improved over the past decades. Clinical trials of anti-HER2 trastuzumab or anti-GD2 dinutuximab for metastatic or refractory osteosarcoma were not successful, and neither was immune checkpoint inhibitors (ICIs). Methods: We tested various target antigen expressions on osteosarcoma cell lines using flow cytometry and analyzed in vitro T cell engaging BsAb (T-BsAb)-dependent T cell-mediated cytotoxicity using 4-h 51 Cr release assay. We tested in vivo anti-tumor activities of T-BsAb targeting GD2 or HER2 in established osteosarcoma cell line or patient-derived xenograft (PDX) mouse models carried out in BALB-Rag2−/−IL-2R-γc-KO (BRG) mice. We also generated ex vivo BsAb-armed T cells (EATs) and studied their tumor-suppressive effect against osteosarcoma xenografts. In order to improve the anti-tumor response, ICIs, anti-human PD-1 (pembrolizumab) or anti-human PD-L1 (atezolizumab) antibodies were tested their synergy with GD2- or HER2-BsAb against osteosarcoma. Results: GD2 and HER2 were chosen from a panel of surface markers on osteosarcoma cell lines and PDXs. Anti-GD2 BsAb or anti-HER2 BsAb exerted potent anti-tumor effect against osteosarcoma tumors in vitro and in vivo. T cells armed with anti-GD2-BsAb (GD2-EATs) or anti-HER2-BsAb (HER2-EATs) showed significant anti-tumor activities as well. Anti-PD-L1 combination treatment enhanced BsAb-armed T cell function in vivo and improved tumor control and survival of the mice, when given sequentially and continuously. Conclusion: Anti-GD2 and anti-HER2 BsAbs were effective in controlling osteosarcoma. These data support the clinical investigation of GD2 and HER2 targeted T-BsAb treatment in combination with immune checkpoint inhibitors, particularly anti-PD-L1, in patients with osteosarcoma to improve their treatment outcome.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13045-020-01012-y

Cites

64 of 64 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 GD2-BsAb and HER2-BsAb exerted strong cytotoxicity against osteosarcoma. a Antibody-dependent T cell-mediated cytotoxicity (ADTC) was analyzed by 51Cr release assay using activated T cells (ET ratio, 10 to 1) at decreasing concentrations of BsAb in an osteosarcoma cell line panel. Cytotoxicity was compared to control BsAb with T cells and each BsAb alone. b In vivo anti-tumor activity of GD2-BsAb and HER2-BsAb against osteosarcoma. c Immunohistochemical (IHC) staining of tumor-infiltrating lymphocytes. Tumors were harvested on day 30 post-treatment and stained with anti-human CD3 antibody (× 200). d IHC staining of tumors by anti-human CD4 and anti-human CD8 antibody (× 200) following treatment with iv PBMC and iv GD2-BsAb
Fig. 1 GD2-BsAb and HER2-BsAb exerted strong cytotoxicity against osteosarcoma. a Antibody-dependent T cell-mediated cytotoxicity (ADTC) was analyzed by 51Cr release assay using activated T cells (ET ratio, 10 to 1) at decreasing concentrations of BsAb in an osteosarcoma cell line panel. Cytotoxicity was compared to control BsAb with T cells and each BsAb alone. b In vivo anti-tumor activity of GD2-BsAb and HER2-BsAb against osteosarcoma. c Immunohistochemical (IHC) staining of tumor-infiltrating lymphocytes. Tumors were harvested on day 30 post-treatment and stained with anti-human CD3 antibody (× 200). d IHC staining of tumors by anti-human CD4 and anti-human CD8 antibody (× 200) following treatment with iv PBMC and iv GD2-BsAbCC BY · PubMed Central
Fig. 2 In vivo anti-tumor activity of ex vivo GD2-BsAb or HER2- BsAb-armed T cells (EATs). a Anti-tumor activities of GD2-EATs and HER2-EATs were tested over a range of BsAb arming concentrations in vivo. b GD2-EATs (10 μg of GD2-BsAb/2 × 107 cells) and HER2-EATs (10 μg of HER2-BsAb/2 × 107 cells) exerted a potent anti-tumor effect against a variety of osteosarcoma PDXs without significant toxicity, improving survival
Fig. 2 In vivo anti-tumor activity of ex vivo GD2-BsAb or HER2- BsAb-armed T cells (EATs). a Anti-tumor activities of GD2-EATs and HER2-EATs were tested over a range of BsAb arming concentrations in vivo. b GD2-EATs (10 μg of GD2-BsAb/2 × 107 cells) and HER2-EATs (10 μg of HER2-BsAb/2 × 107 cells) exerted a potent anti-tumor effect against a variety of osteosarcoma PDXs without significant toxicity, improving survivalCC BY · PubMed Central
Fig. 3 PD-1 and PD-L1 expression by T cells and osteosarcoma cell line xenografts. a Flow cytometry analysis of PD-1 expression on tumor-infiltrating lymphocytes (TILs) in osteosarcoma 143B cell line xenografts on day 35 post-GD2-BsAb treatment. b Flow cytometry analyses of human CD3(+) T cells and human PD-1 expression by CD3(+) T cells in peripheral blood after GD2-BsAb or HER2-BsAb treatment. c IHC staining and flow cytometry analysis of human PD-L1 in osteosarcoma 143B xenografts. PD-L1 expression levels were quantified using geometric MFI (MFI)
Fig. 3 PD-1 and PD-L1 expression by T cells and osteosarcoma cell line xenografts. a Flow cytometry analysis of PD-1 expression on tumor-infiltrating lymphocytes (TILs) in osteosarcoma 143B cell line xenografts on day 35 post-GD2-BsAb treatment. b Flow cytometry analyses of human CD3(+) T cells and human PD-1 expression by CD3(+) T cells in peripheral blood after GD2-BsAb or HER2-BsAb treatment. c IHC staining and flow cytometry analysis of human PD-L1 in osteosarcoma 143B xenografts. PD-L1 expression levels were quantified using geometric MFI (MFI)CC BY · PubMed Central
Fig. 4 Combination of immune checkpoint inhibitors with BsAb treatment. a In vivo anti-tumor effect of PD-1 blockades and GD2-EATs or HER2-EATs combination therapy against osteosarcoma. b Flow cytometric analyses of tumor-infiltrating lymphocytes (TILs) on day 52 (for GD2-EATs) and day 58 (for HER2-EATs) post-treatment. c Fresh-frozen tumor sections were stained with mouse IgG3-3F8, and GD2 expression was scored by staining intensity
Fig. 4 Combination of immune checkpoint inhibitors with BsAb treatment. a In vivo anti-tumor effect of PD-1 blockades and GD2-EATs or HER2-EATs combination therapy against osteosarcoma. b Flow cytometric analyses of tumor-infiltrating lymphocytes (TILs) on day 52 (for GD2-EATs) and day 58 (for HER2-EATs) post-treatment. c Fresh-frozen tumor sections were stained with mouse IgG3-3F8, and GD2 expression was scored by staining intensityCC BY · PubMed Central
Fig. 5 Optimal timing of anti-PD-L1 for combination treatment with GD2-BsAb. a Combination treatment of GD2-EATs and PD-1 blockades: a comparison of 3 different combination schedules of PD-1/PD-L1 antibody [concurrent therapy (CT) vs. sequential therapy (ST) vs. sequentially continuous therapy (SCT)]. b Formalin-fixed paraffin-embedded (FFPE) tumor sections of each group were stained with anti-human CD3 antibody (×200). CD3(+) T cell numbers were compared
Fig. 5 Optimal timing of anti-PD-L1 for combination treatment with GD2-BsAb. a Combination treatment of GD2-EATs and PD-1 blockades: a comparison of 3 different combination schedules of PD-1/PD-L1 antibody [concurrent therapy (CT) vs. sequential therapy (ST) vs. sequentially continuous therapy (SCT)]. b Formalin-fixed paraffin-embedded (FFPE) tumor sections of each group were stained with anti-human CD3 antibody (×200). CD3(+) T cell numbers were comparedCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 64 references

Cited by

See all 88

Metadata

Authors
Park, J. A., & Cheung, N.-K. V.
Affiliations
Memorial Sloan Kettering Cancer Center (US)
Corresponding author
Cheung, Nai-Kong V.
Venue
Journal of Hematology & Oncology
Published
2020-12
Volume
13
Issue
1
Pages
172-172
ISSN
1756-8722 (ISSN-L)
OpenAlex
W3112196236
Cited by
88
References
64
Citations by year
2026: 10 · 2025: 16 · 2024: 22 · 2023: 14 · 2022: 12 · 2021: 14
FWCI
5.62
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Hematology & Oncology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Enid A. Haupt Endowed Chair
  • The Robert Steel Foundation
  • Kids Walk for Kids with Cancer
  • Y-mAbs Therapeutics
  • NCI Cancer Center Support Grant (P30 CA008748)
  • Division of Cancer Epidemiology and Genetics, National Cancer Institute (P30 CA008748)
  • Robert Steel Foundation
Topics
  • Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
  • Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Keywords
osteosarcoma, bispecific antibodies, T cell-engaging antibody, GD2, HER2, PD-L1 inhibitors, immune checkpoint inhibitors, adoptive T cell therapy, ex vivo T cell engineering, pembrolizumab, atezolizumab, patient-derived xenografts, combination immunotherapy
MeSH terms
Antineoplastic Agents, Immunological, Animals, Bone Neoplasms, Gangliosides, Humans, Male, Mice, Inbred BALB C, Osteosarcoma, T-Lymphocytes, Antibodies, Bispecific, Erb-b2 Receptor Tyrosine Kinases, Cell Line, Tumor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma. https://app.cochat.ai/papers/10.1186/s13045-020-01012-y
The paper
Park, J. A., & Cheung, N.-K. V. (2020). GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma. Journal of Hematology & Oncology. https://doi.org/10.1186/s13045-020-01012-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.